NZ
NZM2.STU Novozymes A/S
- Market cap
- -
- P/E
- 44.8x
- P/B
- 2.10x
- ROE
- 6.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is NZM2.STU undervalued?
Graham numberThe Graham number of Novozymes A/S cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Novozymes A/S fundamental analysis
No fundamental analysis for Novozymes A/S yet.
Novozymes A/S stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Novozymes A/S
Novozymes A/S produces and sells industrial enzymes, microorganisms, and biopolymers worldwide. It operates through three divisions: Household Care and Technical Industries, Agriculture and Bioenergy, and Food and Beverages. The company offers solutions for the agriculture industry, including enzymes for animal nutrition to enhance digestion processes; probiotics; microbial solutions to maintain water quality that limits risk of disease and enhances yields in aquaculture; an…
Full company profileNovozymes A/S financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Novozymes A/S annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 14.1B | 14.5B | 14.4B | 14.4B | 14.0B | 2.01B | 2.36B | 2.40B | 3.83B | 4.16B | 4.47B |
| Gross Profit | 8.13B | 8.41B | 8.26B | 7.95B | 7.85B | 1.16B | 1.29B | 1.30B | 1.81B | 2.24B | 2.51B |
| Operating Income | 3.95B | 4.11B | 4.07B | 3.55B | 3.61B | 522M | 594M | 611M | 659M | 883M | 1.07B |
| EBITDA | - | 4.94B | 4.96B | 5.07B | 4.85B | 5.44B | 821M | 734M | 1.04B | 1.39B | 1.07B |
| Net Income | 3.05B | 3.12B | 3.23B | 3.15B | 2.83B | 423M | 493M | 406M | 306M | 584M | 742M |
| EPS | - | 11 | 11 | 11 | 10 | 1.53 | 1.78 | 1.46 | 0.66 | 1.25 | 1.59 |
| Balance Sheet | |||||||||||
| Total Assets | 18.7B | 18.4B | 19.7B | 20.4B | 20.5B | 3.33B | 3.76B | 3.81B | 15.2B | 16.3B | 16.6B |
| Total Liabilities | 6.91B | 7.11B | 8.26B | 8.96B | 9.27B | 1.69B | 1.85B | 1.88B | 4.02B | 5.49B | 5.48B |
| Shareholders' Equity | 11.7B | 11.3B | 11.4B | 11.5B | 11.2B | 1.59B | 1.86B | 1.88B | 11.2B | 10.9B | 11.2B |
| Cash & Short-term Investments | 812M | 632M | 723M | 711M | 1.18B | 129M | 140M | 150M | 280M | 275M | 309M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 3.84B | 4.06B | 3.68B | 3.20B | 4.36B | 4.06B | 4.01B | 557M | 1.02B | 1.22B | 1.05B |
| Capital Expenditure | 1.08B | 1.59B | 1.39B | 997M | 940M | 1.24B | 2.89B | 276M | 360M | 471M | 432M |
| Free Cash Flow | - | 2.37B | 2.29B | 2.20B | 3.42B | 2.82B | 1.12B | 281M | 660M | 751M | 614M |
| Ratios | |||||||||||
| ROE | 26.0% | 27.7% | 28.2% | 27.5% | 25.1% | 26.6% | 26.6% | 21.6% | 2.7% | 5.4% | 6.6% |
| ROA | 16.3% | 17.0% | 16.4% | 15.4% | 13.8% | 12.7% | 13.1% | 10.7% | 2.0% | 3.6% | 4.5% |
| Net Profit Margin | 21.6% | 21.5% | 22.4% | 21.9% | 20.2% | 21.0% | 20.9% | 16.9% | 8.0% | 14.0% | 16.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Novozymes A/S dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- 69.0%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 403M | 0.86 | 69.0% |
| 2024 | EUR 250M | 0.54 | 81.7% |
| 2023 | EUR 383M | 1.38 | 94.4% |
| 2022 | DKK 1.53B | 5.51 | 309.1% |
| 2021 | DKK 1.47B | 5.29 | 346.6% |
| 2020 | DKK 1.48B | 5.31 | 52.5% |
| 2019 | DKK 1.44B | 5.11 | 45.6% |
| 2018 | DKK 1.32B | 4.58 | 40.8% |
| 2017 | EUR 1.19B | 4.07 | 38.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Novozymes A/S
Ownership data of Novozymes A/S is not available yet.
Novozymes A/S company profile
- Company name
- Novozymes A/S
- Ticker
- NZM2.STU
- ISIN
- DK0060336014
- Exchange
- Stuttgart Exchange
- Sector
- -
- Industry
- Oil, Gas & Consumable Fuels
- Employees
- 6,385
- Fiscal year end
- December
- Address
- Krogshoejvej 36, Bagsvaerd, Denmark, 2880
- Phone
- 45 44 46 00 00
- Website
- novozymes.com
About Novozymes A/S
Novozymes A/S produces and sells industrial enzymes, microorganisms, and biopolymers worldwide. It operates through three divisions: Household Care and Technical Industries, Agriculture and Bioenergy, and Food and Beverages. The company offers solutions for the agriculture industry, including enzymes for animal nutrition to enhance digestion processes; probiotics; microbial solutions to maintain water quality that limits risk of disease and enhances yields in aquaculture; and microbial-based biocontrol and bioyield enhancer products to naturally produce healthier crops and enhance yields. It also provides a portfolio of enzymes for application in biofuel production; enzymes for drug delivery and drug formulation; and food and beverages enzymes for applications in baking, brewing, dairy, distilling, flavor enhancement, food specialties, health and nutrition, juice, meat processing, oils and fats, starch, and wine industries. In addition, the company offers household care enzyme and microbial agents for use in cleaning solutions, dishwashing, and laundry; enzymes for biopreparation, degreasing, and re-bating of leather; enzymes for pulp and paper production processes, such as bleach boosting, deinking, drainage enhancement, effluent control, pitch control, refining, slime control, starch modification, and stickies control; enzymatic solutions for processing textiles; and biological wastewater treatment products. Novozymes A/S has a strategic alliance with Monsanto Company to discover, develop, and sell microbial solutions for farmers. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
Novozymes A/S management
5- Mr. Peder Holk NielsenChief Exec. Officer and Pres
- Mr. Benny Dalgaard LoftChief Financial Officer and Exec. VP of Corp. Function
- Mr. Thomas VidebaekChief Operating Officer and Exec. VP of Research, Innovation & Supply
- Mr. Andrew FordyceExec. VP of Food & Beverages
- Mr. Per FalholtConsultant